• May 30, 2021
alidea

Abirateron u metastazujícího karcinomu prostaty

Abirateron u metastazujícího karcinomu prostaty bez předchozí chemoterapie. Abiraterone acetate, an androgen biosynthesis inhibitor, improves total survival in sufferers with metastatic castration-resistant prostate most cancers after chemotherapy. We evaluated this agent in sufferers who had not acquired earlier chemotherapy. METHODS On this double-blind examine, we randomly assigned 1088 sufferers to obtain abiraterone acetate (1000 mg)…

Read More
alidea

Revidovaná kritéria odpovědi pro maligní lymfom

Revidovaná kritéria odpovědi professional maligní lymfom. Standardized response standards are wanted to interpret and examine medical trials and for approval of recent therapeutic brokers by regulatory businesses. METHODS The Worldwide Working Group response standards (Cheson et al, J Clin Oncol 17:1244, 1999) had been extensively adopted, however required reassessment due to recognized limitations and the…

Read More